glp 1 weight loss studies GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis GLP-1 discontinuation: weight-loss drugs work

In these STEP trials, most participants experienced mild to moderate symptoms, with the incidence of severe side effects being 9.8% in the semaglutide treatment group and 6.4% in the placebo group

however, symptoms or abnormal results prompt faster follow-up

Research specifically notes that semaglutide does not appear to compromise immune defense against infections

FMI analysts observe a clear stratification between first-generation GLP-1s optimized for diabetes management and next-generation molecules engineered for weight loss superiority

BMJ Case Rep

Weight gain was associated with increased osteoporosis risk among those not on a GLP-1, while weight gain was not associated with statistically significant change in osteoporosis risk for those on a GLP-1